logo
ENFRع
#

Latest news with #PaulHickey

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Business Wire

time3 days ago

  • Business
  • Business Wire

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

IRVINE, Calif.--(BUSINESS WIRE)--ReShape Lifesciences ® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." 'Vyome's vision is expansive with several promising assets and we are focused on building a healthcare platform spanning the US-India innovation corridor,' said Krishna Gupta, Chairman of Vyome. 'We look forward to trading as a public company under the meaningful ticker symbol 'HIND', which we expect to be on India's Independence Day – August 15. We have a very entrepreneurial and established board and management team, and we have a deep focus on creating value for our new and existing shareholders.' 'We are grateful for the overwhelming support from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction offers a compelling opportunity for our shareholders as Vyome pursues its growth strategy as a Nasdaq-listed public company,' said Paul Hickey, Chief Executive Officer of ReShape. Maxim Group LLC is serving as financial advisor to ReShape in connection with the transactions and Fox Rothschild LLP is acting as its legal counsel. Chardan is serving as financial advisor to Vyome for the merger and Sichenzia Ross Ference Carmel LLP is acting as its legal counsel. About ReShape Lifesciences ® ReShape Lifesciences ® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon ® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Forward-Looking Statements Certain statements contained in this document are "forward-looking statements." Examples of such statements include, but are not limited to, statements relating to the anticipated timing and completion of the proposed merger and the combined company's listing on the Nasdaq Stock Market after closing of the proposed merger. ReShape and/or the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed merger through the process being conducted by the parties. ReShape disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Sentiment on stocks collapses the most since the February market top
Sentiment on stocks collapses the most since the February market top

CNBC

time3 days ago

  • Business
  • CNBC

Sentiment on stocks collapses the most since the February market top

The latest gauge of investor sentiment is rife with uneasiness. Counterintuitively, some market strategists think that could be a bullish sign that forces traders to get back into the market and drive stocks higher. Bearish individual investor sentiment toward stocks over the next six months rose by more than 10 percentage points, the most since February, in the latest weekly survey by the American Association of Individual Investors. More than two-fifths of investors polled, or 43.2%, are now negative on how stocks will perform through the early part of next year, up from 33% last week. The 10.2-point rise was the most since a 20-point increase shortly after the S&P 500 reached a then-record high on Feb. 19. According to Bespoke Investment Group, the week ending in Aug. 6 was just the fourth period since the bull market began in October 2022 that bearish sentiment had a 10-point weekly increase. "The AAII numbers can be volatile at times, and this survey, whether it's due to an older cohort or some other factor tends to be more negative than others," Bespoke co-founder Paul Hickey told CNBC. "I'll be the first to say that certain sectors of the market have gotten frothy, but there's also a non-trivial contingent of people we talk to who are increasingly worried that things are about to fall apart, and that's not usually the sentiment you see around peaks." Investor sentiment is viewed by many as a contrarian indicator. The idea is that when investors are bearish, they are more likely to have already sold stocks and have more cash on hand to put to work. And when more are bullish, the reverse is true. "If the poll is bearish, that is encouraging," Sam Stovall, chief investment strategist at CFRA Research, said in an email. "The institutional investor (smart) money tends to look at retail investors as 'dumb money' and tends to make near-term price performance projections accordingly." Although market volatility has dramatically lowered since the start of the year, a series of negative news and data releases — such as tariff hikes on top trading partners, threats on pharmaceutical tariffs, the Federal Reserve's decision to maintain rates and a weak July jobs report — has weighed on sentiment and kept investors wary of high valuations at bay. At the same time, stocks have chugged along, driven by strength in corporate earnings results and consumer spending, AI enthusiasm, technical strength and more. The three major U.S. indexes are each in the green for the year and are tracking for a weekly gain.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store